Drug intelligence / Profile preview

99mTc-AuNP

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

99mTc-AuNP refers to Technetium-99m labeled gold nanoparticles. It is designed as a diagnostic agent for radionuclide imaging, particularly for cancer targeting. In studies, it serves as a foundational nanoparticle for comparison with more complex formulations, such as those loaded with therapeutic agents like resveratrol, demonstrating its potential for localizing cancerous sites.

Other names: Technetium-99m labeled gold nanoparticlesTechnetium99m labeled gold nanoparticlesTechnetium 99m labeled gold nanoparticles

Targets

NeuraminidaseMRC1 (Mannose Receptor C-type 1)RBM39 (RNA-binding motif protein 39)

Beyond the preview

Go deeper on 99mTc-AuNP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-AuNP.

Explore the full profile